Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=109 A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Uterine Serous Carcinoma
Primary: Objective Response Rate (ORR) — 26 Percentage of participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=20 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
Phase 2 N=56 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Phase 2 N=23 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 2 N=23 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Mixed Tumor, Mullerian
Primary: Number of Participants With Overall Response — 8 participants
Phase 2 N=55 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
Sarcoma
Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants
Phase 2 N=22 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response (Complete or Partial) — 0 percentage of participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=26 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants
Phase 2 N=28 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 2 N=42 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response — 11.8 percentage
Phase 2 N=36 Gemzar, Cisp, Sunitinib Urothelial Ca
Urothelial Cancer
Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=26 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Leiomyosarcoma
Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants
Phase 2 N=26 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Tumor Response — 0 percentage of participants
Phase 2 N=31 Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cancer
Primary: Best Overall Response — 0; 0; 13; 11 participants